Breaking News
October 21, 2018 - Researchers show better cardiorespiratory fitness leads to longer life
October 21, 2018 - Healthy candies for diabetic patients
October 21, 2018 - Environment impact of microplastics remains unclear
October 21, 2018 - Antibiotics for appendicitis? Surgery often not needed
October 21, 2018 - AHA and AMA recognize more than 800 medical practices, health systems for blood pressure control
October 21, 2018 - Scientists obtain clearest ever image of Ebola virus protein
October 21, 2018 - Study reveals connection between two proteins known to be hyperactive in cancer
October 21, 2018 - Gabapentin Beats Pregabalin for Chronic Sciatica
October 21, 2018 - Cosmetic surgeons offering incomplete information for breast augmentation customers
October 21, 2018 - Chronic sleep disruption in early adult life accelerates AD-related tau pathology
October 21, 2018 - Take 10 for Mindfulness – Drugs.com MedNews
October 21, 2018 - Length of breathing disruption in OSA may be better predictor of mortality risk
October 21, 2018 - ApoE4 gene linked with chronic inflammation increases risk for Alzheimer’s disease
October 21, 2018 - Mother-daughter conflict associated with suicide risk in abused adolescent girls
October 21, 2018 - Scientists molding bacteria into unnatural shapes
October 21, 2018 - Discharged mental health patients ‘at greater risk of dying’
October 21, 2018 - As billions in tax dollars flow to private Medicaid plans, Who’s minding the store?
October 21, 2018 - Neuroscientists identify brain region that appears to be related to food preference decisions
October 21, 2018 - Deaths related to air pollution in the U.S. decreased by 47% between 1990 and 2010
October 21, 2018 - Study shows correlation between spatial memory and the sense of smell
October 21, 2018 - Increased cardiorespiratory fitness associated with reduced long-term mortality
October 21, 2018 - IU researchers receive $1.55 million from NIH to improve chronic-disease management
October 21, 2018 - Income and wealth affect the mental health of Australians, study shows
October 21, 2018 - Patients with hypertension and psoriasis more often require cardiovascular interventions
October 20, 2018 - Leading hip-hop videos depict use of tobacco and marijuana products, study finds
October 20, 2018 - Dose Range of IV Ketamine for Adjunct Tx of Depression Tested
October 20, 2018 - Infants can distinguish between leaders and bullies, study finds
October 20, 2018 - Mad Cow disease found on Aberdeenshire farm
October 20, 2018 - Study identifies factors associated with prescription opioid misuse among students
October 20, 2018 - Scientists uncover key regulator of mTORC1 in cancer growth
October 20, 2018 - Pounds Regained After Weight-Loss Op Can Tell Your Doc a Lot
October 20, 2018 - Sending parents letters to fight childhood obesity doesn’t work
October 20, 2018 - Supervised aerobic exercise can support major depression treatment
October 20, 2018 - Mindfulness-based program effective for reducing stress in infertile women
October 20, 2018 - Molecule capable of halting and reverting neurodegeneration caused by Parkinson’s disease identified
October 20, 2018 - Midazolam-mediated alterations of PER2 expression may have functional consequences during myocardial ischemia
October 20, 2018 - Sweat bees are ideal for studying the genes underlying social behavior
October 20, 2018 - Weight loss success associated with brain areas involved in self-control
October 20, 2018 - KHN’s ‘What the Health?’ Republicans’ preexisting political problem
October 20, 2018 - Research provides a more complete picture of suffering caused by terrorist attacks
October 20, 2018 - Eradicating Helicobacter pylori infections may be a key treatment for Parkinson’s disease
October 20, 2018 - Breast Cancer as a Dynamic Disease
October 20, 2018 - University of Pittsburgh wins NSF grant for big data research to prevent complications from anesthesia
October 20, 2018 - Skin-to-skin contact may promote attachment between parents and preterm infants
October 20, 2018 - Recommendations Developed to Verify NGT Placement in Children
October 20, 2018 - Weight loss can be boosted fivefold thanks to novel mental imagery technique
October 20, 2018 - Children with autism are more likely to be overweight, obese
October 20, 2018 - Nurses making conscientious objections to ethically-relevant policies lack support
October 20, 2018 - Prion strain diversity may be greater than previously thought
October 20, 2018 - Antidepressant treatment may lead to improvements in sleep quality of patients with depression
October 20, 2018 - Study reports increased risk of death in children with inflammatory bowel disease
October 20, 2018 - Number of Autism Genes Now Tops 100
October 20, 2018 - Total diet replacement programmes are effective for treating obesity
October 20, 2018 - CLARIOstar used for fluorescence measurements on CSIRO’s purpose-built research vessel
October 20, 2018 - People with more copies of AMY1 gene digest starchy carbohydrates faster
October 20, 2018 - Case Comprehensive Cancer Center wins NIH grant to study health disparities
October 20, 2018 - Newly discovered compound shows potential for treating Parkinson’s disease
October 20, 2018 - High rate of non-adherence to hormonal therapy found among premenopausal early breast cancer patients
October 20, 2018 - Immunotherapy medicine found to be effective in treating uveitis
October 20, 2018 - The Pistoia Alliance Calls for Greater Collaboration to Realise Benefits of Innovation and Announces Winners of the 2018 President’s Startup Challenge
October 20, 2018 - Female internists consistently earn less than men
October 20, 2018 - Stanford team looks at dangers of teens’ vaping habits
October 20, 2018 - New approach to understanding cancers will accelerate development of better treatments
October 20, 2018 - LJI and UC San Diego awarded $ 4.5 million as part of NCI’s Cancer Moonshot initiative
October 20, 2018 - School-based HPV vaccination did not increase risky sexual behaviors among adolescent girls
October 20, 2018 - Eye discovery to pave way for more successful corneal transplants
October 20, 2018 - New analysis examines the importance of location in the opioid crisis
October 20, 2018 - Green filters increase reading speed for children with dyslexia
October 19, 2018 - Bariatric Sx Cuts Macrovascular Complications in Obesity, T2DM
October 19, 2018 - Better assessments for early age-related macular degeneration
October 19, 2018 - Visible and valued: Stanford Medicine’s first-ever LGBTQ+ Forum | News Center
October 19, 2018 - Understanding of metal-free enzymes used by bacteria could lead to new effective antibiotics
October 19, 2018 - Beckman Coulter Life Sciences announces new research-focused website
October 19, 2018 - Study finds link between refined soluble fibers, gut microbiota and liver cancer
October 19, 2018 - Social media reduces risk of depression among seniors with pain
October 19, 2018 - Newly developed synthetic DNA molecule may one day be used as ‘vaccine’ for prostate cancer
October 19, 2018 - Preoperative weight loss may not provide health benefits after surgery
October 19, 2018 - U.S. Birth Rates Continue to Drop as Age of New Moms Rises
October 19, 2018 - New technology can keep an eye on babies’ movements in the womb
October 19, 2018 - Juul e-cigarettes pose addiction risk for young users | News Center
First Successful Gene Therapy for Hemophilia A

First Successful Gene Therapy for Hemophilia A

image_pdfDownload PDFimage_print

Action Points

  • This landmark study demonstrated the feasibility of gene transfer to normalize factor VIII levels in adults with hemophilia A.
  • Modest transaminase elevation was common, but self-limited.

ATLANTA — A single infusion of a gene therapy for hemophilia A led to normalization of factor VIII levels that persisted for a year, British investigators reported here.

Six of seven patients treated with the highest dose of the engineered therapy had factor VIII levels >50 IU/dL, and the seventh patient had therapeutic levels of factor VIII at 1 year. The high-dose cohort averaged 16 bleeding episodes a year before treatment and one episode afterward.

The most frequent adverse event was elevated serum alanine aminotransferase (ALT), reported K. John Pasi, MB ChB, PhD, of the Royal London Hospital, at the American Society of Hematology (ASH) meeting. The results were published simultaneously in the New England Journal of Medicine.

“Increases in factor VIII activity levels were dose dependent, with all seven participants in the high-dose cohort sustaining therapeutic levels at 1 year after gene transfer,” Pasi’s group noted in the published article. “In conjunction, the frequency of participant-treated bleeding episodes decreased markedly, with resultant cessation of factor VIII use. The absence of spontaneous bleeding in patients with severe hemophilia A factor VIII replacement therapy, regardless of the product half-life.”

The study is the first successful demonstration of gene therapy for hemophilia, as three previous trials with different genetically engineered products either failed to show a benefit, they added.

Combined with reported success for gene therapy for the less common hemophilia B, the results suggest that a cure for hemophilia may soon be within reach, according to the author of an accompanying editorial.

“These landmark studies … are leading the way to a cure for hemophilia,” wrote H. Marijke van den Berg, MD, PhD, of PedNet Hemophilia Research Foundation in Baarn, the Netherlands. “Prophylaxis with coagulation products could be discontinued in each study, and bleeding rates were reduced to zero, which is to be expected when factor VIII and factor IX levels are sustained at levels exceeding 5 IU per deciliter.”

If the initial results hold up in additional clinical evaluations, “children born with this devastating disease could benefit from a life without bleeding and other sequelae of the disease,” van den Berg added.

During an advance ASH media preview, Robert Brodsky, MD, of Johns Hopkins in Baltimore, included the gene therapy trial in a small group of abstracts that he characterized as “home run-type” studies. Like van den Berg, he said the impressive 52-week results suggest the engineered therapy offers a potential cure for hemophilia A.

The small clinical trial evaluated the safety and efficacy of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding a B-domain-deleted human factor VIII (AAV5). Until the successful results presented by Pasi’s group, the large size of the factor VIII coding region had posed a seemingly insurmountable obstacle improved outcomes in hemophilia A with gene therapy.

Preclinical evaluations of AAV5 (valoctocogene roxaparvovec) showed dose-dependent increases in factor VIII expression in mouse and nonhuman primate models of hemophilia A, providing a rationale for clinical evaluation. Investigators evaluated three doses of the gene therapy in a total of nine men with severe hemophilia A. Low and intermediate doses of the gene therapy (administered to one patient each) failed to achieve and maintain therapeutic levels of factor VIII.

Safety was the primary objective of the trial, and clinical efficacy was a secondary objective. The seven participants in the high-dose cohort and the patient who received the lowest dose of the gene therapy had increased ALT, which was asymptomatic and resolved without intervention or sequelae.

All seven patients in the high-dose cohort achieved therapeutic levels of factor VIII by week 16, the prespecified time point for efficacy assessment. The 5 IU/dL definition for therapeutic level is the cutoff between moderate and mild hemophilia.

“After week 20, the factor VIII activity level was consistently more than 50 IU per deciliter in six of seven participants, and in the remaining participant, the level typically ranged from 12 to 32 IU per deciliter,” the authors noted.

At week 52, the median factor VIII activity level for the high-dose cohort was 77 IU/dL.

In addition to the decline in bleeding episodes that accompanied the increase in factor VIII levels, the requirement for factor VIII also declined dramatically. The median annualized use of factor VIII decreased from 138 infusions per year pre-study to two infusions per year following gene therapy.

Analysis of biologic fluids and stool samples showed that residual vector DNA decreased over the course of the study period.

The authors pointed out that they did not assess the possibility of vector integration, and that the study protocol was not “designed to measure whether AAV5 infection was present in family members or close contacts.”

Pasi disclosed relevant relationships with Bayer HealthCare, Biotest, Novo Nordisk, Pfizer, Roche, SOBI, Octapharma, Shire, Alnylam, Biomarin, and Biogen Idec.

Van den Berg disclosed relevant relationshps with Bayer, CSL, NovoNordisk, Pfizer, Grifols, Sobi, and Bioverativ.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-12-09T09:04:50-0500

Tagged with:

About author

Related Articles